Cargando…

Lactoferrin Prevents Hepatic Injury and Fibrosis via the Inhibition of NF-κB Signaling in a Rat Non-Alcoholic Steatohepatitis Model

Non-alcoholic steatohepatitis (NASH) can cause liver cirrhosis and hepatocellular carcinoma (HCC), with cases increasing worldwide. To reduce the incidence of liver cirrhosis and HCC, NASH is targeted for the development of treatments, along with viral hepatitis and alcoholic hepatitis. Lactoferrin...

Descripción completa

Detalles Bibliográficos
Autores principales: Aoyama, Yoshinaga, Naiki-Ito, Aya, Xiaochen, Kuang, Komura, Masayuki, Kato, Hiroyuki, Nagayasu, Yuko, Inaguma, Shingo, Tsuda, Hiroyuki, Tomita, Mamoru, Matsuo, Yoichi, Takiguchi, Shuji, Takahashi, Satoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746867/
https://www.ncbi.nlm.nih.gov/pubmed/35010924
http://dx.doi.org/10.3390/nu14010042
_version_ 1784630693669634048
author Aoyama, Yoshinaga
Naiki-Ito, Aya
Xiaochen, Kuang
Komura, Masayuki
Kato, Hiroyuki
Nagayasu, Yuko
Inaguma, Shingo
Tsuda, Hiroyuki
Tomita, Mamoru
Matsuo, Yoichi
Takiguchi, Shuji
Takahashi, Satoru
author_facet Aoyama, Yoshinaga
Naiki-Ito, Aya
Xiaochen, Kuang
Komura, Masayuki
Kato, Hiroyuki
Nagayasu, Yuko
Inaguma, Shingo
Tsuda, Hiroyuki
Tomita, Mamoru
Matsuo, Yoichi
Takiguchi, Shuji
Takahashi, Satoru
author_sort Aoyama, Yoshinaga
collection PubMed
description Non-alcoholic steatohepatitis (NASH) can cause liver cirrhosis and hepatocellular carcinoma (HCC), with cases increasing worldwide. To reduce the incidence of liver cirrhosis and HCC, NASH is targeted for the development of treatments, along with viral hepatitis and alcoholic hepatitis. Lactoferrin (LF) has antioxidant, anti-cancer, and anti-inflammatory activities. However, whether LF affects NASH and fibrosis remains unelucidated. We aimed to clarify the chemopreventive effect of LF on NASH progression. We used a NASH model with metabolic syndrome established using connexin 32 (Cx32) dominant negative transgenic (Cx32ΔTg) rats. Cx32ΔTg rats (7 weeks old) were fed a high-fat diet and intraperitoneally injected with dimethylnitrosamine (DMN). Rats were divided into three groups for LF treatment at 0, 100, or 500 mg/kg/day for 17 weeks. Lactoferrin significantly protected steatosis and lobular inflammation in Cx32ΔTg rat livers and attenuated bridging fibrosis or liver cirrhosis induced by DMN. By quantitative RT–PCR, LF significantly down-regulated inflammatory (Tnf-α, Il-6, Il-18, and Il-1β) and fibrosis-related (Tgf-β1, Timp2, and Col1a1) cytokine mRNAs. Phosphorylated nuclear factor (NF)-κB protein decreased in response to LF, while phosphorylated JNK protein was unaffected. These results indicate that LF might act as a chemopreventive agent to prevent hepatic injury, inflammation, and fibrosis in NASH via NF-κB inactivation.
format Online
Article
Text
id pubmed-8746867
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87468672022-01-11 Lactoferrin Prevents Hepatic Injury and Fibrosis via the Inhibition of NF-κB Signaling in a Rat Non-Alcoholic Steatohepatitis Model Aoyama, Yoshinaga Naiki-Ito, Aya Xiaochen, Kuang Komura, Masayuki Kato, Hiroyuki Nagayasu, Yuko Inaguma, Shingo Tsuda, Hiroyuki Tomita, Mamoru Matsuo, Yoichi Takiguchi, Shuji Takahashi, Satoru Nutrients Article Non-alcoholic steatohepatitis (NASH) can cause liver cirrhosis and hepatocellular carcinoma (HCC), with cases increasing worldwide. To reduce the incidence of liver cirrhosis and HCC, NASH is targeted for the development of treatments, along with viral hepatitis and alcoholic hepatitis. Lactoferrin (LF) has antioxidant, anti-cancer, and anti-inflammatory activities. However, whether LF affects NASH and fibrosis remains unelucidated. We aimed to clarify the chemopreventive effect of LF on NASH progression. We used a NASH model with metabolic syndrome established using connexin 32 (Cx32) dominant negative transgenic (Cx32ΔTg) rats. Cx32ΔTg rats (7 weeks old) were fed a high-fat diet and intraperitoneally injected with dimethylnitrosamine (DMN). Rats were divided into three groups for LF treatment at 0, 100, or 500 mg/kg/day for 17 weeks. Lactoferrin significantly protected steatosis and lobular inflammation in Cx32ΔTg rat livers and attenuated bridging fibrosis or liver cirrhosis induced by DMN. By quantitative RT–PCR, LF significantly down-regulated inflammatory (Tnf-α, Il-6, Il-18, and Il-1β) and fibrosis-related (Tgf-β1, Timp2, and Col1a1) cytokine mRNAs. Phosphorylated nuclear factor (NF)-κB protein decreased in response to LF, while phosphorylated JNK protein was unaffected. These results indicate that LF might act as a chemopreventive agent to prevent hepatic injury, inflammation, and fibrosis in NASH via NF-κB inactivation. MDPI 2021-12-23 /pmc/articles/PMC8746867/ /pubmed/35010924 http://dx.doi.org/10.3390/nu14010042 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Aoyama, Yoshinaga
Naiki-Ito, Aya
Xiaochen, Kuang
Komura, Masayuki
Kato, Hiroyuki
Nagayasu, Yuko
Inaguma, Shingo
Tsuda, Hiroyuki
Tomita, Mamoru
Matsuo, Yoichi
Takiguchi, Shuji
Takahashi, Satoru
Lactoferrin Prevents Hepatic Injury and Fibrosis via the Inhibition of NF-κB Signaling in a Rat Non-Alcoholic Steatohepatitis Model
title Lactoferrin Prevents Hepatic Injury and Fibrosis via the Inhibition of NF-κB Signaling in a Rat Non-Alcoholic Steatohepatitis Model
title_full Lactoferrin Prevents Hepatic Injury and Fibrosis via the Inhibition of NF-κB Signaling in a Rat Non-Alcoholic Steatohepatitis Model
title_fullStr Lactoferrin Prevents Hepatic Injury and Fibrosis via the Inhibition of NF-κB Signaling in a Rat Non-Alcoholic Steatohepatitis Model
title_full_unstemmed Lactoferrin Prevents Hepatic Injury and Fibrosis via the Inhibition of NF-κB Signaling in a Rat Non-Alcoholic Steatohepatitis Model
title_short Lactoferrin Prevents Hepatic Injury and Fibrosis via the Inhibition of NF-κB Signaling in a Rat Non-Alcoholic Steatohepatitis Model
title_sort lactoferrin prevents hepatic injury and fibrosis via the inhibition of nf-κb signaling in a rat non-alcoholic steatohepatitis model
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746867/
https://www.ncbi.nlm.nih.gov/pubmed/35010924
http://dx.doi.org/10.3390/nu14010042
work_keys_str_mv AT aoyamayoshinaga lactoferrinpreventshepaticinjuryandfibrosisviatheinhibitionofnfkbsignalinginaratnonalcoholicsteatohepatitismodel
AT naikiitoaya lactoferrinpreventshepaticinjuryandfibrosisviatheinhibitionofnfkbsignalinginaratnonalcoholicsteatohepatitismodel
AT xiaochenkuang lactoferrinpreventshepaticinjuryandfibrosisviatheinhibitionofnfkbsignalinginaratnonalcoholicsteatohepatitismodel
AT komuramasayuki lactoferrinpreventshepaticinjuryandfibrosisviatheinhibitionofnfkbsignalinginaratnonalcoholicsteatohepatitismodel
AT katohiroyuki lactoferrinpreventshepaticinjuryandfibrosisviatheinhibitionofnfkbsignalinginaratnonalcoholicsteatohepatitismodel
AT nagayasuyuko lactoferrinpreventshepaticinjuryandfibrosisviatheinhibitionofnfkbsignalinginaratnonalcoholicsteatohepatitismodel
AT inagumashingo lactoferrinpreventshepaticinjuryandfibrosisviatheinhibitionofnfkbsignalinginaratnonalcoholicsteatohepatitismodel
AT tsudahiroyuki lactoferrinpreventshepaticinjuryandfibrosisviatheinhibitionofnfkbsignalinginaratnonalcoholicsteatohepatitismodel
AT tomitamamoru lactoferrinpreventshepaticinjuryandfibrosisviatheinhibitionofnfkbsignalinginaratnonalcoholicsteatohepatitismodel
AT matsuoyoichi lactoferrinpreventshepaticinjuryandfibrosisviatheinhibitionofnfkbsignalinginaratnonalcoholicsteatohepatitismodel
AT takiguchishuji lactoferrinpreventshepaticinjuryandfibrosisviatheinhibitionofnfkbsignalinginaratnonalcoholicsteatohepatitismodel
AT takahashisatoru lactoferrinpreventshepaticinjuryandfibrosisviatheinhibitionofnfkbsignalinginaratnonalcoholicsteatohepatitismodel